Tempus AI Stock Rallies 105% in a Year: Should Investors Still Hold?

Key Takeaways TEM stock gained 105% in a year as Genomics and Data results exceeded expectations for 2025. Tempus earned multiple FDA 510(k) clearances, expanding its AI-based diagnostics and imaging portfolio. TEM delivered positive adjusted EBITDA, though GAAP losses continue due to compensation and amortization. Tempus AI (TEM) stock has delivered a remarkable 105% gain over the past year, driven by strong performance across both its Genomics and Data segments, surpassing initial expectations for 2025. A ...